- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00515437
A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
April 29, 2019 updated by: Solstice Neurosciences
A Multi-Center, Randomized, Double-blind, Placebo-Controlled,Sequential Dose Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
To determine safety, tolerability and preliminary efficacy of intraglandular injections of MYOBLOC for the treatment of sialorrhea in Parkinsons' Disease patients
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a multi-center, outpatient, double-blind, placebo-controlled, single treatment, sequential dose escalation study designed to evaluate the safety, tolerability and preliminary efficacy of single doses of MYOBLOC versus placebo for the treatment of sialorrhea in Parkinson's disease patients, lasting approximately 20 weeks.
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Dr Virgilio Evidente
-
-
California
-
Northridge, California, United States, 91325
- Dr. Ronald Ziman
-
Oxnard, California, United States, 93030
- Dr. James Sutton
-
-
Colorado
-
Denver, Colorado, United States, 80262
- Dr. Olga Klepitskaya
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Dr. Fernando Pagan
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Dr Hubert Fernandez
-
-
Georgia
-
Atlanta, Georgia, United States, 30329
- Dr. Alan Freeman
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Dr. Katie Kompoliti
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Dr. Robert Rodnitzky
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Dr. Stephen Reich
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Dr. Brad Racette
-
-
New York
-
Albany, New York, United States, 12205
- Dr. Eric Molho
-
-
Rhode Island
-
Warwick, Rhode Island, United States, 02886
- Dr. Joseph Friedman
-
-
South Carolina
-
Charleston, South Carolina, United States, 29401
- Dr. Vanessa Hinson
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37923
- Dr. Sam Kabbani
-
-
Texas
-
Dallas, Texas, United States, 75231
- Dr. Madhavi Thomas
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Dr. Gordon Smith
-
-
Washington
-
Tacoma, Washington, United States, 98405
- Dr. Patrick Hogan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 83 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Parkinsons' Disease patients with Sialorrhea for at least 3 months
Exclusion Criteria:
- Patients with non-idiopathic PD parkinsonism
- Patients previously exposed to botulinum toxins
- Patients with a history of aspiration pneumonia, moderate/severe choking and/or moderate/severe dysphagia
- Patients with prior salivary gland surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
1500U Myobloc
|
|
Experimental: 2
2500U Myobloc
|
|
Experimental: 3
3500U Myobloc
|
|
Placebo Comparator: 4
pooled placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Drooling Frequency & Severity Scale (DFSS)at Wk 4 Post-injection
Time Frame: baseline versus 4 weeks post-injection
|
9 point scale, 0 = no drooling, 9 = severe drooling
|
baseline versus 4 weeks post-injection
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Drooling Frequency and Severity Scale (DFSS) at Wk 12 Post-injection
Time Frame: baseline vs 12 weeks post injection
|
9 point scale (0=no drooling, 9=severe drooling)
|
baseline vs 12 weeks post injection
|
Change in Unstimulated Salivary Flow Rate at Wk 4 Post-injection
Time Frame: baseline vs 4 weeks post-injection
|
saliva is collected over 5 minutes and weighed to produce a grams/minute "rate"
|
baseline vs 4 weeks post-injection
|
Change in Unstimulated Salivary Flow Rate at Wk 12 Post-injection
Time Frame: baseline vs 12 weeks post-injection
|
saliva collected over 5 minutes and weighed to produce a grams/minute "rate"
|
baseline vs 12 weeks post-injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Eric Pappert, MD, Solstice Neurosciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2007
Primary Completion (Actual)
June 1, 2008
Study Completion (Actual)
September 1, 2008
Study Registration Dates
First Submitted
August 10, 2007
First Submitted That Met QC Criteria
August 10, 2007
First Posted (Estimate)
August 13, 2007
Study Record Updates
Last Update Posted (Actual)
May 7, 2019
Last Update Submitted That Met QC Criteria
April 29, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Stomatognathic Diseases
- Mouth Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Salivary Gland Diseases
- Parkinson Disease
- Sialorrhea
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Anti-Dyskinesia Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
- rimabotulinumtoxinB
Other Study ID Numbers
- SN-SIAL-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drooling
-
NeuroHealing Pharmaceuticals Inc.Michael J. Fox Foundation for Parkinson's ResearchCompletedSialorrhea (Excessive Drooling)France
-
Maharishi Markendeswar University (Deemed to be...Completed
-
Hospices Civils de LyonCompletedCerebral Palsy | Pathological Drooling
-
Hadassah Medical OrganizationUnknown
-
Isra UniversityUnknown
-
Hospices Civils de LyonRecruiting
-
Cairo UniversityCompletedCerebral Palsy | Drooling | KinesiotapeEgypt
-
National Taiwan University HospitalNational Science Council, TaiwanUnknownCerebral Palsy | DroolingTaiwan
-
Hacettepe UniversityCompleted
-
Centre Médico-Chirurgical de Réadaptation des Massues...CompletedCerebral Palsy | DroolingFrance
Clinical Trials on Botulinum Toxin Type B (Myobloc)
-
Georgetown UniversitySolstice NeurosciencesCompletedStroke | Brain Injury | Tumor | Spinal Cord Injury (SCI) | Spasticity Secondary to Either a Disorder or TraumaUnited States
-
Supernus Pharmaceuticals, Inc.Solstice NeurosciencesActive, not recruitingMultiple Sclerosis | Cerebral Palsy | Traumatic Brain Injury | Cerebrovascular Accident | Cervical Spinal Cord Injury | SpasticityUnited States, Czechia
-
Columbia UniversitySolstice NeurosciencesCompletedFocal DystoniaUnited States
-
Supernus Pharmaceuticals, Inc.Solstice NeurosciencesActive, not recruitingSpasticityUnited States, Czechia
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
Solstice NeurosciencesCompleted
-
The University of Texas Health Science Center at...ALS Association; University of Kansas; Carolinas MDA Neuromuscular/ALS Center-Carolinas...CompletedAmyotrophic Lateral Sclerosis | SialorrheaUnited States
-
Supernus Pharmaceuticals, Inc.CompletedSialorrheaUnited States, Ukraine, Belarus
-
Daewoong Pharmaceutical Co. LTD.Completed
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States